Agreements reached under this partnership
Joint venture- 1
Manufacture, sale and export of blood bags
- 2
Following the start of plant operations in 2029, the joint venture is expected to develop a more stable blood-related business through local production.
- 3
The joint venture aims to expand its business into the MENA region (the Middle East and North Africa), using Egypt as its base.
- 4
We will strengthen the resilience of our supply chain through the geographic diversification of production bases.
- 5
Local production of blood bags using Japanese technology will contribute to improving the quality of healthcare in Egypt.
- 6
The joint venture will contribute to the development of Egypt’s pharmaceutical and medical device industries by creating local employment and transferring technology.
- 7
The joint venture is expected to contribute to improving healthcare infrastructure throughout the MENA region.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Following the start of plant operations in 2029, the joint venture plans to develop its business with a view to exporting to the MENA region in the future.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
| Item | Details |
|---|---|
| Name of alliance partner | Egyptian Company for Medical Investments (S.A.E.), INTERPHARM for Import, Export & Medical Industries (S.A.E.) |
| Alliance partner's business activities | Egyptian government-affiliated healthcare investment company, Egypt-based pharmaceutical and medical device manufacturing and sales company |
| Alliance partner's location | Egypt |
| Type of alliance | Joint venture |
| Details of the alliance | Manufacture, sale and export of blood bags, Following the start of plant operations in 2029, the joint venture is expected to develop a more stable blood-related business through local production., The joint venture aims to expand its business into the MENA region (the Middle East and North Africa), using Egypt as its base., We will strengthen the resilience of our supply chain through the geographic diversification of production bases., Local production of blood bags using Japanese technology will contribute to improving the quality of healthcare in Egypt., The joint venture will contribute to the development of Egypt’s pharmaceutical and medical device industries by creating local employment and transferring technology., The joint venture is expected to contribute to improving healthcare infrastructure throughout the MENA region. |
| Shareholding ratio | Not disclosed → JMS Singapore Pte. Ltd 18% |
| Overview of the joint venture | Name Japan-Egypt Blood Bag (JMS) S.A.E. / Location Ain Sokhna Industrial Zone, plot 2, sector I-A, Egypt / Business Description Manufacture, sale and export of blood bags / Capital Contributions 12,500,000 EGP / Ownership ratio Egyptian Company for Medical Investments (S.A.E.) 41%、INTERPHARM for Import, Export & Medical Industries (S.A.E.) 41%、JMS Singapore Pte. Ltd 18% |
| Ownership ratio | Egyptian Company for Medical Investments (S.A.E.) 41% / INTERPHARM for Import, Export & Medical Industries (S.A.E.) 41% / JMS Singapore Pte. Ltd 18% |
| Numerical targets under the alliance | Following the start of plant operations in 2029, the joint venture plans to develop its business with a view to exporting to the MENA region in the future. |
| Contract Date | 30 April 2025 |
| Alliance start date | 7 April 2026 (establishment of the joint venture) |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Against the backdrop of the Egyptian government’s policy to localize pharmaceutical and medical device production, the initiative aims to ensure a stable supply and quality of blood bags, improve healthcare quality through local production, create jobs and transfer technology, expand the business into the MENA region, and strengthen the supply chain.